High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells

Cell Death Dis. 2022 Nov 4;13(11):924. doi: 10.1038/s41419-022-05375-7.

Authors

Meng-Yuan Dai^#^{1

2

3}, Yu-Ying Shi^#^{1

2

3}, An-Jin Wang^{1

2

3}, Xue-Lian Liu^{1

2

3}, Miao Liu⁴, Hong-Bing Cai^{5

6

7}

Affiliations

¹ Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
² Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China.
³ Hubei Cancer Clinical Study Center, Wuhan, China.
⁴ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. mliu0@bwh.harvard.edu.
⁵ Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China. chb21051@163.com.
⁶ Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China. chb21051@163.com.
⁷ Hubei Cancer Clinical Study Center, Wuhan, China. chb21051@163.com.

^# Contributed equally.

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

B7-H1 Antigen* / metabolism
Cell Line, Tumor
Humans
Neoplasms* / metabolism
Peptides / pharmacology
Programmed Cell Death 1 Receptor / metabolism

Substances

B7-H1 Antigen
Peptides
Programmed Cell Death 1 Receptor